Prostate cancer medicine hailed as a "milestone" breakthrough may not be available to every patient after a revision of the drug guidelines, according to the NHS.
Men in England who have already been treated with a new-generation cancer drug would not be eligible for Enzalutamide, according to the National Institute for Health and Care Excellence (Nice).
Nice, the public body which decides the cost-effectiveness of medicines for NHS patients, said the new drug should not be used by patients who had already taken abiraterone.
Enzalutamide blocks molecular signals driving prostate cancer and improved survival by 30% in men who had not undergone chemotherapy.
A further 80% of men with advanced cancer had the progression delayed, even if the tumour had failed to respond to other treatments.
More top news
Lucy Beale's killer will be revealed live on air during a special week of EastEnders episodes to mark the soap's 30th anniversary.
Spandau Ballet reunited on stage for the first time in five years as the band performed at the premiere of a film documenting their career.
From tomorrow, tax discs will no longer be needed to show drivers have paid their vehicle tax. Richard Pallot reports on the end of an era.